Collaboration in more than 46 countries.

You are leaving the country website to access another site in the group. Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.

NORTH AMERICA

Canada

United States

LATIN AMERICA

Argentina

Brazil

Mexico

Perú

GLOBAL

CEVA Global

EMEA (REGIONAL)

Denmark

Egypt

France

Germany

Hungary

Italy

Netherlands

Poland

Portugal

Romania

South Africa

Spain

Sweden

Tunisia

Turkey

Ukraine

United Kingdom

ASIA PACIFIC

Asia Pacific (Regional)

CHINA

India

Indonesia

Japan

Korea

Malaysia

Philippines

Publications
PDF

Poster-1_-Eprecis_Achard_2017_EBF-2017.pdf

Open PDF

Summary

Good syringeability is important to facilitate the use of injectable products in the field and to ensure compliance. Eprecis® 2% ” (Ceva, Eprinomectin 20 mg/mL) has demonstrated a significant better syringeability than the other two products tested with the two different needles tested. The superior performance can be explained by the active ingredient and the different excipients used in their formulation. This high fluidity strongly increases the comfort and convenience of use in the field.

Share this publication:

Publication file:

Download publication
This site is registered on wpml.org as a development site.